Swine producers need to carefully evaluate the costs of prevention versus treatment when it comes to disease in their herds.

“We need to try to categorize the different types of diseases, as to whether it has a real good type of treatment, a low cost type of treatment, or maybe a high cost animal health problem if we do get it in the herd, and then start making animal health management decisions based on that,” said Iowa State University ag economist Dr. Jim Kliebenstein at the Boehringer Ingelheim swine health seminar in North Carolina on Friday.

One point he made is that “total prevention” of any disease is probably unaffordable. “Maybe getting it to where there’s only a ten percent chance or a five percent chance, but once we get above that, the costs of going to even greater lengths far exceed the benefits,” he said.

Kliebenstein presented the economic impact of swine disease, especially PRRS, both from a personal level and on an average per producer and for the industry. He was a partner in a gilt multiplier herd when they had an outbreak of PRRS that caused them to lose their contract. “We lost a significant number of dollars,” he related. “We had gilts that were on the books at $250 because we had a production contract. Overnight, they went to $50 or less.”

Overall, Kleibenstein estimates the annual cost of just PRRS to the U.S. swine industry at $600-800 million a year and could increase to $1 billion if the disease incidence keeps growing. He strongly recommends that producers do their homework and determine what works best for their operations to control and prevent swine diseases.

BIVI swine health seminar photo album

Listen to or download an interview with Dr. Jim Kliebenstein here: